- Home
- CELU vs VRCA Comparison
CELU vs VRCA Comparison
Compare CELU & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- VRCA
- Stock Information
- Founded
- CELU 2016
- VRCA 2013
- Country
- CELU United States
- VRCA United States
- Employees
- CELU N/A
- VRCA N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- VRCA Health Care
- Exchange
- CELU Nasdaq
- VRCA Nasdaq
- Market Cap
- CELU 37.7M
- VRCA 43.0M
- IPO Year
- CELU N/A
- VRCA 2018
- Fundamental
- Price
- CELU $2.11
- VRCA $0.49
- Analyst Decision
- CELU
- VRCA Hold
- Analyst Count
- CELU 0
- VRCA 5
- Target Price
- CELU N/A
- VRCA $6.00
- AVG Volume (30 Days)
- CELU 91.2K
- VRCA 263.8K
- Earning Date
- CELU 05-08-2025
- VRCA 05-13-2025
- Dividend Yield
- CELU N/A
- VRCA N/A
- EPS Growth
- CELU N/A
- VRCA N/A
- EPS
- CELU N/A
- VRCA N/A
- Revenue
- CELU $54,220,000.00
- VRCA $7,179,000.00
- Revenue This Year
- CELU $23.29
- VRCA $127.85
- Revenue Next Year
- CELU N/A
- VRCA $105.09
- P/E Ratio
- CELU N/A
- VRCA N/A
- Revenue Growth
- CELU 138.11
- VRCA N/A
- 52 Week Low
- CELU $1.00
- VRCA $0.38
- 52 Week High
- CELU $5.22
- VRCA $9.36
- Technical
- Relative Strength Index (RSI)
- CELU 54.10
- VRCA 42.86
- Support Level
- CELU $1.90
- VRCA $0.49
- Resistance Level
- CELU $2.47
- VRCA $0.73
- Average True Range (ATR)
- CELU 0.29
- VRCA 0.07
- MACD
- CELU 0.01
- VRCA -0.01
- Stochastic Oscillator
- CELU 58.25
- VRCA 21.79
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.